



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C12N 15/12, 15/85, 5/10, C07K 14/47, A61K 38/17</b>		A2	(11) International Publication Number: <b>WO 97/00319</b>
(21) International Application Number: PCT/GB96/01388		(43) International Publication Date: 3 January 1997 (03.01.97)	(41) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 11 June 1996 (11.06.96)			
(30) Priority Data: 9511935.0 13 June 1995 (13.06.95) GB			
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			
(72) Inventors; and			Published
(75) Inventors/Applicants (for US only): BROWNE, Michael, Joseph [GB/GB]; (GB). CHAPMAN, Conrad, Gerald [GB/GB]; (GB). CLINKENBEARD, Helen, Elizabeth [GB/GB]; (GB). ROBINSON, Jeffrey, Hugh [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).			Without international search report and to be republished upon receipt of that report.
(74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).			

(54) Title: CHIMERIC LEPTIN FUSED TO IMMUNOGLOBULIN DOMAIN AND USE

## (57) Abstract

Chimeric leptin which are proteins comprising leptin or a mutant or a variant thereof fused to a human immunoglobulin domain. One favoured immunoglobulin domain is the human immunoglobulin Fc domain. The chimeric derivatives of leptin have, despite their large molecular size, good pharmacological activity combined with prolonged clearance rates. These derivatives of leptin are therefore indicated to be particularly useful for the treatment or prophylaxis of obesity or diseases and conditions associated with obesity such as atherosclerosis, hypertension and type II diabetes.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**CHIMERIC LEPTIN FUSED TO IMMUNOGLOBULIN DOMAIN AND USE**

The present invention relates to a novel compound being a novel chimeric protein, to a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine, especially for the treatment of obesity and associated diseases.

European Patent Application, Publication number 0 464 533 discloses fusion proteins comprising various portions of the constant region of immunoglobulin molecules together with another human protein or part thereof. European Patent Application, Publication number 0 297 882 discloses fusion proteins comprising various portions of the plasminogen molecule with part of another human protein.

Zhang et al. (Nature: 372, 425 - 432; 1994) describe the positional cloning of a mouse obese gene and its human homologue. The sequence of the Open Reading Frame (ORF) of the mouse gene predicts a polypeptide of 167 amino acids and Zhang et al. predicted the presence of a signal sequence which would lead to the production of a mature protein of 146 residues. The human homologue was disclosed as having a similar size of 146 amino acids for the mature protein. Zhang et al. showed the presence of a primary translation product of approximate size of 18 kilodaltons (kD) with truncation to a 16kD product on addition of microsomal membranes, consistent with the production of a pre-protein and the removal of an N-terminal signal sequence. Zhang et al also disclose the potential use of the human obese gene product (hereinafter 'leptin') in the treatment of obesity.

For effective, practical treatment of obesity a particularly desirable property of an obesity agent is a clearance rate in humans commensurate with patient acceptable treatment regimens, especially regimens for injectable therapies. Zhang et al. do not disclose information relating to the clearance rate of the active molecule in either mouse or humans.

The precise mechanism of action of leptin is currently unknown, however it is considered that in order to provide the observed pharmacological effects, leptin must interact with one or more receptors in the brain.

We have now discovered certain chimeric derivatives of leptin which surprisingly, despite their large molecular size, have good pharmacological activity combined with prolonged clearance rates. These chimeric derivatives of leptin are therefore indicated to be particularly useful for the treatment or prophylaxis of obesity and for the treatment or prophylaxis of diseases and conditions associated with obesity, such as atherosclerosis, hypertension and, especially, Type II diabetes. In particular these compounds are considered to be useful for administration by injection.

These compounds are also considered to be useful in cosmetic treatments for the improvement of body appearance.

Accordingly, the invention provides a chimeric leptin or a chimeric mutant or derivative of leptin.

5 One particular chimeric leptin is a protein comprising leptin or a mutant or variant thereof fused to a human immunoglobulin domain or a mutant or variant thereof.

Suitably, the chimeric protein comprises one human immunoglobulin domain.

Favourably, the human immunoglobulin domain is fused to the C-terminus of leptin.

10 One favoured human immunoglobulin is an human immunoglobulin Fc domain.

An example of a human immunoglobulin Fc domain is an IgG4PE variant in particular IgG4 hinge-CH<sub>2</sub>-CH<sub>3</sub>PE. Other examples are IgG4, IgG1 and IgG1GT, in particular the hinge-CH<sub>2</sub>-CH<sub>3</sub> region in each case.

15 The term "mutant or variant" used with respect to a particular protein encompasses any molecule such as a truncated or other derivative of the relevant protein which retains substantially the same activity in humans as the relevant protein. Such other derivatives can be prepared by the addition, deletion, substitution, or rearrangement of amino acids or by chemical modifications thereof.

20 The immunoglobulin may be of any subclass (IgG, IgM, IgA, IgE), but is preferably IgG, such as IgG1, IgG3 or IgG4. The said constant domain(s) or fragment thereof may be derived from the heavy or light chain or both. The invention encompasses mutations in the immunoglobulin component which eliminate undesirable properties of the native immunoglobulin, such as Fc receptor binding and/or introduce desirable properties such as stability. For example, Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Roberts G., Pedley B. and Adair R., Molecular Immunology vol30pp105-108, 1993, describe an IgG4 molecule where residue 241 (Kabat numbering) is altered from serine to proline. This change increases the serum half-life of the IgG4 molecule. Canfield S.M. and Morrison S.L., Journal of Experimental Medicine vol173pp1483-1491, describe the alteration of residue 248 (Kabat numbering) from leucine to glutamate in IgG3 and from glutamate to leucine in mouse IgG2b. Substitution of leucine for glutamate in the former decreases the affinity of the immunoglobulin molecule concerned for the Fc<sub>Y</sub>RI receptor, and substitution of glutamate for leucine in the latter increases the affinity. EP0307434 discloses various mutations including an L to E mutation at residue 248 (Kabat numbering) in IgG.

30 35 The constant domain(s) or fragment thereof is preferably the whole or a substantial part of the constant region of the heavy chain of human IgG. The IgG

component suitably comprises the CH<sub>2</sub> and CH<sub>3</sub> domains and the hinge region including cysteine residues contributing to inter-heavy chain disulphide bonding.

For example when the IgG component is derived from IgG4 it includes cysteine residues 8 and 11 of the IgG4 hinge region (Pinck J.R. and Milstein C., Nature 5 vol216pp941-942, 1967). Preferably the IgG4 component consists of amino acids corresponding to residues 1-12 of the hinge, 1-110 of CH<sub>2</sub> and 1-107 of CH<sub>3</sub> of IgG4 described by Ellison J., Buxbaum J. and Hood L., DNA vol1pp11-18, 1981. In one example of a suitable mutation in IgG4, residue 10 of the hinge (residue 241, Kabat numbering) is altered from serine (S) in the wild type to proline (P) and residue 5 of CH<sub>2</sub> (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).

DNA polymers which encode mutants or variants of the human immunoglobulin may be prepared by site-directed mutagenesis of the cDNA which codes for the required protein by conventional methods such as those described by G. Winter *et al* in Nature 15 1982, 299, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., 10, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter *et al* in Biochem. Soc. Trans., 1984; 12, 224-225 or polymerase chain reaction such as described by Mikaelian and Sergeant in Nucleic Acids Research, 1992, 20, 376.

When used herein 'compound of the invention' or 'compounds of the invention' relates to the above mentioned chimera.

In a further aspect, the invention provides a process for preparing a compound according to the invention which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product.

The DNA polymer comprising a nucleotide sequence that encodes the compound also forms part of the invention.

The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis *et. al.*, Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982 and DNA Cloning vols I, II and III (D.M. Glover ed., 30 IRL Press Ltd.).

In particular, the process may comprise the steps of:

- i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said compound;
- ii) transforming a host cell with said vector;
- 35 iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said compound; and
- iv) recovering said compound.

The invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.

The preparation may be carried out chemically, enzymatically, or by a combination of the two methods, *in vitro* or *in vivo* as appropriate. Thus, the DNA 5 polymer may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D. M. Roberts *et al* in Biochemistry 1985, 24, 5090-5098.

The DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical 10 synthesis, by enzymatic polymerisation on DNA or RNA templates, or by a combination of these methods.

Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50µl or less with 0.1-10µg DNA.

Enzymatic polymerisation of DNA may be carried out *in vitro* using a DNA 15 polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50µl or less.

Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, 20 generally in a volume of 50µl or less.

The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, 25 Weinheim (1982), or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H. Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; S.P. 30 Adams *et al.*, Journal of the American Chemical Society, 1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H.W.D. Matthes *et al.*, EMBO Journal, 1984, 3, 801. Preferably an automated DNA synthesizer is employed.

The DNA polymer is preferably prepared by ligating two or more DNA 35 molecules which together comprise a DNA sequence encoding the compound. A particular process in accordance with the invention comprises ligating a first DNA

molecule encoding a said leptin or variant and a second DNA molecule encoding a said immunoglobulin domain or fragment thereof.

The DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences or by use of polymerase chain reaction technology.

The precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the desired product. The design of a suitable strategy for the construction of the DNA molecule coding for the compound is a routine matter for the skilled worker in the art.

The expression of the DNA polymer encoding the compound in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer. The expression vector is novel and also forms part of the invention.

The replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment, encode the compound, under ligating conditions.

The ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired.

Thus, the DNA polymer may be preformed or formed during the construction of the vector, as desired.

The choice of vector will be determined in part by the host cell, which may be prokaryotic, such as *E. coli*, or eukaryotic, such as mouse C127, mouse myeloma, Chinese hamster ovary, Cos1 or Hela cells, fungi e.g. filamentous fungi or unicellular yeast or an insect cell such as Drosophila. The host cell may also be a transgenic animal.

A preferred host cell is Cos1.

Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses derived from, for example, baculoviruses, vaccinia or Semliki Forest virus.

The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis *et al.*, cited above.

Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50µl or less with 0.1-10µg DNA.

The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis *et al.*, cited above, or "DNA Cloning" Vol. II, D.M. 5 Glover ed., IRL Press Ltd, 1985.

The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as *E. coli* may be treated with a solution of CaCl<sub>2</sub> (Cohen *et al.*, Proc. 10 Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl<sub>2</sub>, potassium acetate and glycerol, and then with 3-[N-morpholino]-propane-sulphonic acid, RbCl and glycerol. Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells.

The invention also extends to a host cell transformed or transfected with a replicable expression vector of the invention.

Culturing the transformed host cell under conditions permitting expression of the 15 DNA polymer is carried out conventionally, as described in, for example, Maniatis *et al* and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45°C.

The expression product is recovered by conventional methods according to the 20 host cell. Thus, where the host cell is bacterial, such as *E. coli* it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. If the product is to be secreted from the bacterial cell it may be recovered from the periplasmic space or the nutrient medium. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium.

The DNA polymer may be assembled into vectors designed for isolation of stable 25 transformed mammalian cell lines expressing the product; e.g. bovine papillomavirus vectors or amplified vectors in chinese hamster ovary cells (DNA cloning Vol.II D.M. Glover ed. IRL Press 1985; Kaufman, R.J. *et al.*, Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H., Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, D.V. *et al.*, European Patent Application 30 No. 0093619, 1983).

The activity of the chimeric leptin is determined by injecting it intraperitoneally, 35 intravenously or subcutaneously into test animals such as rodents, for example mice or rats, or primates, for example rhesus monkeys. In order to maximise activity, the test animals are preferably overweight or obese animals that have been made overweight by feeding them on a high fat or other palatable diet, or have acquired fat through the ageing process. In the case of mice, however, the ideal strain is the genetically obese (ob/ob) mouse. The effect of the active compound is seen as a reduction in food intake or increase

in metabolic rate or oxygen consumption. Multiple injections of the active compound - at most twice daily - over a period of a week for rodents or a month for primates, also cause a reduction in body weight and in the size of discrete adipose tissue depots.

5 Clearance rates are determined by conventional plasma assay using ob-antibodies, for example ELISA methodology.

As indicated above the compounds of the present invention have useful pharmaceutical properties, in particular anti obesity activity and also for the treatment of diseases associated with obesity, such as atherosclerosis, hypertension and, especially, Type II diabetes.

10 In use the compound will normally be employed in the form of a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will depend on the mode of administration.

15 The active compound may be formulated for administration by any suitable route and is preferably in unit dosage form. Advantageously, the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration or through the respiratory tract. Preparations may be designed to give slow release of the active ingredient.

20 The compositions of the invention may be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions. Topical formulations are also envisaged where appropriate.

The invention therefore further provides a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier.

25 The dosage ranges for administration of the compounds of the present invention are those to produce the desired therapeutic effect. Dosage will generally vary with age, extent or severity of the medical condition and contraindications, if any. For example in the treatment of obesity the unit dosage can vary from less than 1mg to 300mg, but typically will be in the region of 1 to 20mg per dose, in one or more doses, such as one to six doses per day, such that the daily dosage is in the range 0.02-40mg/kg.

30 Dosages and compositions for the treatment of diseases associated with obesity such as atherosclerosis, hypertension and, especially, Type II diabetes are selected from an equivalent range to that used in the treatment of obesity.

• Compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use.

• 35 Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle. The compound, depending on the vehicle and concentration used, can be

either dissolved or suspended in the vehicle. Solutions may be used for all forms of parenteral administration, and are particularly used for intravenous infection. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and/or local anaesthetic agents may be dissolved in the vehicle.

5      Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area. Alternatively the drug and other ingredients may be dissolved in an aqueous vehicle, the solution is sterilised by filtration and distributed into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.

10     Parenteral suspensions, suitable for intramuscular, subcutaneous or intradermal injection, are prepared in substantially the same manner, except that the sterile compound is suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration. The compound may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma irradiation.

15     Advantageously, a suspending agent for example polyvinylpyrrolidone is included in the composition to facilitate uniform distribution of the compound.

20     Compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation. In the latter case, particle size of less than 50 microns, especially less than 10 microns, is preferred. Such compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices.

25     In a further aspect there is provided a method of treating obesity or diseases associated with obesity, such as atherosclerosis, hypertension and, especially, Type II diabetes, in human or non-human mammals which comprises administering to the sufferer an effective, non-toxic amount of a compound of the invention.

30     Suitable non-human mammals are domestic mammals such as dogs and cats.

35     The invention further provides a compound of the invention for use as an active therapeutic substance, in particular for use in treating obesity or diseases associated with obesity, such as atherosclerosis, hypertension and, especially, Type II diabetes.

The invention also provides the use of a compound of the invention in the manufacture of a medicament for treating obesity or diseases associated with obesity, such as atherosclerosis, hypertension and, especially, Type II diabetes.

As indicated above the invention also encompasses cosmetic treatments.

5 Accordingly, there is also provided a compound of the invention for use in the cosmetic treatment of human or non-human mammals.

There is also provided a method for the cosmetic treatment of a human or non-human mammal, which treatment comprises administering an effective, non-toxic amount of a compound of the invention to a human or non-human mammal in need 10 thereof.

Cosmetic treatment suitably includes treatment for the improvement of body appearance, such as weight reduction treatment.

The invention also extends to a cosmetic composition, comprising a compound of the invention and a carrier therefor.

15 Compositions of the invention including cosmetic compositions are formulated using known methods, for example those described in standard text books of pharmaceutics and cosmetics, such as Harry's Cosmeticology published by Leonard Hill Books, Remington's Pharmaceutical Sciences, the British and US Pharmacopoeias.

No unexpected toxicological effects are expected when compounds of the 20 invention are administered in accordance with the present invention.

The following Examples illustrate the invention but do not limit it in any way.

**Example 1.****Construction of DNA coding for fusion protein leptin 1-167/IgG4 hinge-CH2-CH3**

The gene coding for a fusion protein comprising human leptin and the

5 hinge-CH2-CH3 region of human IgG4 is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.

The human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.

10 The cDNA encoding full length human leptin, nucleotides 1-501 is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgG4 protein, shown as nucleotides 502-1188 in the DNA sequence below. (Table 1.)

The encoded protein sequence of the leptin/IgG4 chimera is given in Table 2.

Leptin 1-167 (numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold

& J. Friedman. Nature 372:425-432), and IgG4 hinge-CH2-CH3 168-396 (*sequence as Kabat*).

15 The fusion protein was expressed transiently in Cos1 cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388.

The mature protein was exported from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to have a size consistent with the predicted structure by 20 Western blotting analysis under both reducing and nonreducing conditions.

**Table 1. DNA sequence of ob/IgG4 chimera, 1188bp**

25	ATGCATTGGGAAACCTGTGCGGATTCTGTGGCTTGGCCCTATCTTCTATGTCAA 60
30	GCTGTGCCATCCAAAAAGTCCAAGATGACACCAAAACCCTCATCAAGACAATTGTCACC 120
35	AGGATCAATGACATTCACACACCGCAGTCAGTCTCCTCCAAACAGAAAGTCACCGGTTG 180
40	GACTTCATTCTGGCTCCACCCATCCTGACCCGTCCAAGATGGACCAGACACTGGCA 240
45	GTCTACCAACAGATCCTCACATCGATGCCTTCCAGAACGTGATCCAAATATCCAACGAC 300
50	CTGGAGAACCTCCGGGATCTTCTCACGTGCTGGCCTCTCTAAGAGCTGCCACTTGCCC 360
	TGGGCCAGTGGCCTGGAGACCTGGACAGCCTGGGGGTGTCCTCGAGGCTTCAGGCTAC 420
	TCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGTCTCTGCAGGACATGCTGTGGCAG 480
	CTGGACCTCAGCCCCGGTGCAGTCCAAATATGGTCCCCATGCCCATGCCAGCA 540

CCTGAATTCTGGGGGACCATCAGTCTTCTGTTCCCCAAAACCCAAGGACACTCTC  
600

5 ATGATCTCCCGAACCCCTGAGGTACGTGCGTGGTGGACGTGAGCCAGGAAGACCCC  
660

GAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCG  
720

10 CGGGAGGAGCAGTTCAACACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG  
780

15 GACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCGTCATCG  
840

ATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTG  
900

20 CCCCCATCCCAGGAGGAGATGACCAAGAACCAAGGTACGCCTGACCTGCCTGGTCAAAGGC  
960

TTCTACCCCAGCGACATGCCGTGGAGTGGAGAGCAATGGCAGCCGGAGAACAACTAC  
1020

25 AAGACCACGCCTCCCGTGGACTCCGACGGATCCTCTACAGCAGGCTAACCC  
1080

30 GTGGACAAGAGCAGGTGGCAGGAGGGAAATGTCTCATGCTCCGTGATGCATGAGGCT  
1140

CTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTGGTAAA  
1188

35

**Table 2. Amino acid sequence of leptin/IgG4 chimera, 396aa**

40 1 MHWGTLGFL WLWPYLFYVQ AVPIQKVQDD TKTLIKTIVT  
RINDISHTQS

51 VSSKQKVTLGL DFIPGLHPL TLSKMDQTLA VYQQILTSMP SRNVIQISND

45 101 LENLRDLLHV LAFSKSCHLP WASGLETLDS LGGVLEASGY  
STEVVVALSRL

151 QGSLQDMLWQ LDLSPGCESK YGPPCPSCPA PEFLGGPSVF  
LFPPKPKDTL

50 201 MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP  
REEQFNSTYR

251 VVSVLTVLHQ DWLNGKEYK CKVSNKGLPSS IEKTISKAKG  
QPREPQVYTL

301 PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY  
5 KTTPPVLDSD

351 GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK

Example 2.**Construction of DNA coding for fusion protein ob 1-167/IgG4 hinge-CH2-CH3 PE variant**

5 The gene coding for a fusion protein comprising the human 'ob' protein and the Hinge-CH2-CH3 region of human IgG4 PE (a form of IgG4 mutated as below) is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.

10 The cDNA coding for the complete human leptin, amino acids 1-167 (numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372: 425-432) is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgG4 (PE variant) protein, shown as amino acids 168-396 in the protein sequence below.

15 The human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector. The encoded protein sequence is given in Table 2.

Human IgG4 heavy chain PE variant. In IgG4 PE, residue 10 of the hinge (residue 241, Kabat numbering) is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the 20 wild type to glutamate (E). Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Roberts G., Pedley B. and Adair R., Molecular Immunology vol30pp105-108, 1993, describe an IgG4 molecule where residue 241 (Kabat numbering) is altered from serine to proline. This change increases the serum half-life of the IgG4 molecule.

25 The IgG4 PE variant was created using PCR mutagenesis on the synthetic human IgG4 heavy chain cDNA. The sequence of the IgG4 PE variant is described in Table 1. The residues of the IgG4 nucleotide sequence which were altered to make the PE variant are as follows:

referring to Table 1:

30 residue 322 has been altered to "C" in the PE variant from "T" in the wild type;

residue 333 has been altered to "G" in the PE variant from "A" in the wild type; and

residues 343-344 have been altered to "GA" in the PE variant from "CT" in the wild type.

35 The fusion protein was expressed transiently in Cos1 cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388. The mature protein was exported from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to have a size consistent with the predicted structure by 40 Western blotting analysis under both reducing and nonreducing conditions.

**Table 3. DNA sequence of IgG4 PE variant, 984bp**

5 SEQ ID No:1  
GCTAGTACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG  
10 AGCACgGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACC GG TGACGGT GTCG  
15 TGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCC GG CTGTCCTACAGT CCTCA  
20 GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGACGAAGACC  
25 TACACCTGCAACGTAGATCACAAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCC  
30 AAATATGGTCCCCCATGCCCAccATGCCAGCgCCTGAaTTtgaGGGGGGACCATCAGTC  
35 TTCCTGTTCCCCCAAAACCAAGGACACTCTCATGATCTCCGGACCCCTGAGGT CACG  
40 TGC GTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAA CTGGTACGTGGAT  
45 GGC GTGGAGGTGCATAATGCCAAGACAAAGCCGGGAGGAGCAGTTCAA ACAGCACGTAC  
50 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAAGGACTGGCTGAACGGCAAGGAGTACAAG  
55 TGCAAGGTCTCCAACAAAGGCCTCCCGTCA TCgATCGAGAAAACC ATCTCCAAAGCCAAA  
60 GGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCTCCAGGAGGAGATGACCAAG  
65 AACCAAGGTCA GCCTGACCTGCCTGGTCAAAGGCTTCTACCCAGCGACATGCCGTGGAG  
70 TGGGAGAGCAATGGGCAGCCGGAGAACAAACTACAAGACCACGCCCTCCGTGCTGGACTCC  
75 GACGGATCCTTCTCCTACAGCAGGCTAACCGTGGAAGAGCAGGTGGCAGGAGGGG  
80 AATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAAACCACTACACACAGAAGAGC  
85 CTCTCCCTGTCTGGTAAATGA  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880

**Table 3A: DNA sequence of ob/IgG4PE chimera, 1188bp**

45 ATGCATTGGGAAACCCTGTGCGGATTCTTGTGGCTTGGCCCTATCTTTCTATGTCCAA  
60 GCTGTGCCCATCCAAAAAGTCCAAGATGACACCAAAACCCCTCATCAAGACAATTGTCAAC  
120 AGGATCAATGACATTCACACACCGCAGTCAGTCTCCTCCAAACAGAAAGTCACCGGTTG  
50 180 GACTTCATTCCCTGGGCTCCACCCCCATCCTGACCCCTGTCCAAGATGGACCAGACACTGGCA  
240 GTCTACCAACAGATCCTCACATCGATGCCTTCCAGAAACGTGATCCAAATATCCAACGAC  
300

CTGGAGAACCTCCGGGATCTTCTCACGTGCTGGCCTCTAAGAGCTGCCACTGCC  
 5 360  
 TGGGCCAGTGGCCTGGAGACCTGGACAGCCTGGGGGTGTCCTCGAGGCTCAGGCTAC  
 420  
 TCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGTCTCTGCAGGACATGCTGTGGCAG  
 480  
 CTGGACCTCAGCCCCGGGTGCGAGTCAAATATGGTCCCCATGCCAcCATGCCAGCg  
 540  
 10 CCTGAATTGAGGGGGGACCATCAGTCTCCTGTTCCCCAAAACCCAAGGACACTCTC  
 600  
 ATGATCTCCGGACCCCTGAGGTACGTGCGTGGTGGACGTGAGCCAGGAAGACCCC  
 660  
 15 GAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCG  
 720  
 CGGGAGGAGCAGTTAACACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCTGCACCAAG  
 780  
 GACTGGCTGAACGGCAAGGAGTACAAGTCAAGGTCTCCAACAAAGGCCTCCGTACATCG  
 840  
 20 ATCGAGAAAACCCTCCTCAAAGCCAAGGGCAGCCCCGAGAGCCACAGGTGTACACCC  
 900  
 CCCCATCCCAGGAGGAGATGACCAAGAACCAAGGTACGCCTGACCTGCCTGGTCAAAGGC  
 960  
 TTCTACCCCAGCGACATGCCGTGGAGTTGGAGAGCAATGGCAGCCGGAGAACAACTAC  
 1020  
 25 AAGACCAACGCCTCCGTGGACTCCGACGGATCCTCTTCCCTACAGCAGGCTAAC  
 1080  
 GTGGACAAGAGCAGGTGGCAGGAGGGAAATGTCTTCTCATGCTCCGTGATGCATGAGGCT  
 1140  
 30 CTGCACAAACCACTACACACAGAAGAGCCTCTCCCTGTCTGGTAAA  
 1188

**Table 4: Amino acid sequence of ob 1-167/IgG4 hinge-CH2-CH3 PE variant chimera  
396aa**

35 SEQ ID No: 2

1 MHWGTLCGFL WLWPYLFYVQ AVPIQKVQDD TKTLIKTIVT RINDISHTQS  
 40 51 VSSKQKVVTGL DFIPGLHPII TLSKMDQTLA VYQQILTSMP SRNVIQISND  
 101 LENLRDLLHV LAFSKSCHLP WASGLELDS LGGVLEASGY STEVVVALSRL  
 151 QGSLQDMLWQ LDLSPGCESK YGPPCPPCPA PEFEGGPSVF LFPPKPKDTL  
 45 201 MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR  
 251 VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL  
 50 301 PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNQOPENNY KTPPPVLDSD

351 GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK

Example 3.

5 **Construction of DNA coding for fusion protein leptin 1-167/IgG1 hinge-CH2-CH3**

The gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgG1 is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.

10 The human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.

The cDNA encoding full length human leptin, nucleotides 1-501 is joined at the 3' end to the 5' end of the hinge-CH2-CH3 region of the cDNA coding for the human IgG1 protein, shown as nucleotides 502-1197 in the DNA sequence below. (Table 1.)

15 The encoded protein sequence of the leptin/IgG1 chimera is given in Table 2. Leptin 1-167 (numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372: 425-432) and IgG1 hinge-CH2-CH3 shown as amino acids 168-399.

20 The gene coding for the human IgG1 contains a number of nucleotide substitutions compared to the IgG1 molecule described by Ellison J.W., Berson B.J. and Hood L.E., Nucleic Acids Research vol 10 No. 13 pp4071-4079, 1982. The IgG1 nucleotides which differ from the Ellison J.W. et al published sequence and the resulting amino acid substitutions are as follows ( nucleotide numbering as in table 1)

25 nucleotide 513 is "G" in this variant compared to "T" in the Ellison et al sequence (silent mutation)

nucleotides 514-516 are "GCC" in this variant compared to "TGT" in the Ellison et al sequence (resulting in substitution of Ala for Cys in this variant, amino acid 172 in table 2)

30 nucleotide 759 is "T" in this variant compared to "G" in the Ellison et al sequence (silent mutation)

35 nucleotide 924 is "G" in this variant compared to "T" in the Ellison et al sequence (resulting in substitution of Glu for Asp in this variant, amino acid 308 in table 2)

nucleotide 928 is "A" in this variant compared to "C" in the Ellison et al sequence (resulting in substitution of Met for Val in this variant, amino acid 310 in table 2)

40 nucleotide 1077 is "T" in this variant compared to "C" in the Ellison et al sequence (silent mutation)

nucleotide 1197 is "G" in this variant compared to "A" in the Ellison et al sequence (silent mutation)

45 The fusion protein was expressed transiently in Cos1 cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388.

The mature protein was exported from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.

5

**Table 5. DNA sequence of ob/IgG1 chimera 1197bp**

	ATGCATTGGGAAACCCTGTGCGGATTCTTGTGGCTTGGCCCTATCTTTCTATGTCAA	60
10	GCTGTGCCATCCAAAAAGTCCAAGATGACACCAAAACCCTCATCAAGACAATTGTCACC	120
15	AGGATCAATGACATTCACACACGCAGTCAGTCTCCTCCAAACAGAAAGTCACCGGTTG	180
	GACTTCATTCTGGCTCCACCCATCCTGACCTGTCCAAGATGGACCAGACACTGGCA	240
20	GTCTACCAACAGATCCTCACATCGATGCCTTCCAGAACGTGATCCAAATATCCAACGAC	300
	CTGGAGAACCTCCGGATCTTCTTCACGTGCTGGCCTCTCTAAGAGCTGCCACTGCC	360
25	TGGGCCAGTGGCCTGGAGACCTTGGACAGCCTGGACAGCCTGGGGGTGTCCTCGAGGCTTCAGGCTAC	420
	TCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGTCTCTGCAGGACATGCTGTGGCAG	480
30	CTGGACCTCAGCCCCGGTGCAGGCCAAATGGCCGACAAAACACACATGCCAACCG	540
35	TGCCCAAGCACCTGAACCTGGGGGACCGTCAGTCTCCTCTCCCCAAAACCCAAG	600
	GACACCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGGACGTGAGCCAC	660
40	GAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAG	720
	ACAAAGCCGGGGAGGAGCAGTACAACACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTC	780
45	CTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC	840
	CCAGCCCCATCGAGAAAACCATCTCCAAAGCAAAGGGCAGCCCCGAGAACCAACAGGTG	900
50	TACACCCTGCCCCATCCCAGGGAGGAGATGACCAAGAACCAAGGTCAACCTGACCTGCCG	960

GTCAAAGGCTTCTATCCCAGCGACATGCCGTGGAGTGGAGAGCAATGGGCAGCCGGAG  
 1020  
 5 AACAACTACAAGACCACGCCCTCCCGTGGACTCCGACGGCTCCTCTCCTCTATAGC  
 1080  
 AAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGAACGTCTTCATGCTCCGTGATG  
 1140  
 10 CATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGTAAG  
 1197

15 **Table 6. Amino acid sequence of leptin/IgG1 chimera, 399aa**

1 MHWGTLCGFL WLWPYLFYVQ AVPIQKVQDD TKTLIKTIYT RINDISHTQS  
 51 VSSKQKVTLGL DFIPGLHPIL TLSKMDQTLA VYQQILTSMP SRNVIQISND  
 20 101 LENLRDLLHV LAFSKSCHLP WASGLELDS LGGVLEASGY STEVVVALSRL  
 151 Q GSLQDMLWQ LDLSPGCEPK SADKTHTCPP CPAPELLGGP SVFLFPPKPK  
 25 201 D TL MISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS  
 251 TYR VVS VLT V LH QDW LNG KE Y KCK VSN KAL PAPI EKTISK AKG QP REP QV  
 30 301 Y TL PPS REEM TKN QVSL T CL VKGF YPS DIA VE WES NGQ PE N NYK TTPP VL  
 351 D SD GS FFLYS KLT VDK SRW Q QGN VFSC SVM HEAL HN HYT Q KSL SLSPG K

35

**Example 4.**

40 **Construction of DNA coding for fusion protein leptin 1-167/IgG1 hinge-CH2-CH3  
GT linker variant**

45 The gene coding for a fusion protein comprising human leptin and the hinge-CH2-CH3 region of human IgG1 with a 'GT' two amino acid linker between the two parts of the fusion molecule, is created by recombinant DNA technology, preferably by a two-step recombinant PCR method.

The human 'ob' gene has been prepared synthetically based on the amino acid sequence of Zhang et al, and assembled in the pcDNA3 vector.

The cDNA encoding the full length human leptin (nucleotides 1-501) is joined at the 3' end to the 5' end of the hinge-CH<sub>2</sub>-CH<sub>3</sub> region of the IgG1 cDNA (nucleotides 508-1203). The two amino acid linker between the two parts of the fusion is encoded by the nucleotide sequence GGTACC (502-507). See Table 1.

5        The encoded protein sequence of the leptin/IgG1(GT) chimera is given in Table 2. Leptin 1-1 (numbering as Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold & J. Friedman. Nature 372:425-432), followed by the GT linker (168-169) and IgG1 H-CH<sub>2</sub>-CH<sub>3</sub> 170-401.

10      The gene coding for the human IgG1 contains a number of nucleotide substitutions compared to the IgG1 molecule described by Ellison J.W., Berson B.J. and Hood L.E., Nucleic Acids Research vol 10 No. 13 pp4071-4079, 1982. The IgG1 nucleotides which differ from the Ellison J.W. et al published sequence and the resulting amino acid substitutions are as follows ( nucleotide numbering as in table 1)

15      nucleotide 519 is "G" in this variant compared to "T" in the Ellison et al sequence (silent mutation)

20      nucleotides 520-522 are "GCC" in this variant compared to "TGT" in the Ellison et al sequence (resulting in substitution of Ala for Cys in this variant, amino acid 174 in table 2)

25      nucleotide 759 is "T" in this variant compared to "G" in the Ellison et al sequence (silent mutation)

30      nucleotide 924 is "G" in this variant compared to "T" in the Ellison et al sequence (resulting in substitution of Glu for Asp in this variant, amino acid 308 in table2)

35      nucleotide 928 is "A" in this variant compared to "C" in the Ellison et al sequence (resulting in substitution of Met for Val in this variant, amino acid 310 in table 2)

40      nucleotide 1077 is "T" in this variant compared to "C" in the Ellison et al sequence (silent mutation)

45      nucleotide 1197 is "G" in this variant compared to "A" in the Ellison et al sequence (silent mutation)

50      The fusion protein was expressed transiently in Cos1 cells using the pCDN vector system, as described in International Patent Application Publication number WO 96/04388. The mature protein was exported from the cells into the culture medium and was detected by anti-leptin antibody. It was shown to have a size consistent with the predicted structure by Western blotting analysis under both reducing and nonreducing conditions.

55      **Table 7. DNA sequence of ob/IgG1'GT' chimera , 1203bp**

ATGCATTGGGAAACCTGTGCGGATTCTTGTGGCTTGCCCTATCTTTCTATGTCCAA

60

45

GCTGTGCCATCCAAAAAGTCCAAGATGACACCAAAACCTCATCAAGACAATTGTCACC  
120

5 AGGATCAATGACATTACACACACCGCAGTCAGTCTCCTCCAAACAGAAAGTCACCGGTTG  
180

10 GACTTCATTCTGGGCTCCACCCCCATCCTGACCCGTCCAAGATGGACCAGACACTGGCA  
240

15 GTCTACCAACAGATCCTCACATCGATGCCTCCAGAAACGTGATCCAAATATCCAACGAC  
300

20 CTGGAGAACCTCCGGGATCTTCTTCACGTGCTGGCCTCTTAAGAGCTGCCACTGCC  
360

25 TGGGCCAGTGGCCTGGAGACCTGGACAGCCTGGGGGTGTCCTCGAGGCTTCAGGCTAC  
420

30 TCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGTCTCTGCAGGACATGCTGTGGCAG  
480

35 CTGGACCTCAGCCCCGGGTGCGGTACCGAGCCAAATCGGCCGACAAAACACACATGC  
540

40 CCACCGTGCCCAGCACCTGAACCTGGGGGACCGTCAGTCTCCTCTTCCCCCAAAA  
600

45 CCCAAGGACACCCCTCATGATCTCCGGACCCCTGAGGTACATGCGTGGTGGACGTG  
660

50 AGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAAT  
720

55 GCCAAGACAAAGCCGGAGGAGCAGTACAACACGACGTACCGTGTGGTACGCGTCCTC  
780

60 CACCGTCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA  
840

65 GCCCTCCCAGCCCCATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCCCCGAGAACCA  
900

70 CAGGTGTACACCCTGCCCATCCGGAGGAGATGACCAAGAACAGGTACGCCGTGACC  
960

75 TGCCTGGTCAAAGGCTTCTATCCCAGCGACATGCCGTGGAGTGGAGAGCAATGGCAG  
1020

80 CGGGAGAACAACTACAAGACCACGCCCTCCGTGCTGGACTCCGACGGCTCCTCTC  
1080

85 TATAGCAAGCTACCGTGGACAAGAGCAGGTGGCAGCAGGGAACGTCTCTCATGCTCC  
1140

90 GTGATGCATGAGGCTCTGCACAAACACTACACGCAGAAGAGCCTCTCCGTCTCCGGGT  
1200

AAG  
1203

5

**Table 8. Amino acid sequence of leptin/IgG1 'GT' chimera, 401aa**

1    MHWGTLCGFL WLWPYLFYVQ AVPIQKVQDD TKTLIKTIVT  
10   RINDISHTQS

51   VSSKQKVVTGL DFIPGLHPII TLSKMDQTLA VYQQILTSMP SRNVIQISND

101   LENLRDLLHV LAFSKSCHLP WASGLELDS LGGVLEASGY  
15   STEVVVALSRL

151   QGSLQDMLWQ LDLSPGCGTE PKSADKTHTC PPCPAPELLG  
GPSVFLFPPK

20   201 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN  
AKTKPREEQY

25   251 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI  
SKAKGQPREP

30   301 QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ  
PENNYKTTPP

35   351 VLDSDGGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY  
TQKSLSLSPG

401   K

35

## Claims:

1. Chimeric leptin or a chimeric mutant or derivative of leptin.
- 5 2. A chimera according to claim 1, wherein the leptin is human leptin.
3. A chimera according to claim 1 or claim 2, wherein the leptin or a mutant or variant thereof is fused to a human immunoglobulin domain or a mutant or variant thereof.
- 10 4. A chimera according to any one of claims 1 to 3, wherein the chimeric protein comprises one human immunoglobulin domain.
5. A chimera according to claim 4, wherein the human immunoglobulin domain is fused to the C-terminus of leptin.
- 15 6. A chimera according to any one of claims 1 to 4, which comprises a human immunoglobulin Fc domain.
7. A chimera according to claim 6, wherein the human immunoglobulin Fc domain is an IgG4PE variant, an IgG4, IgG1 or an IgG1GT variant, in particular the hinge-CH<sub>2</sub>-CH<sub>3</sub> region in each case.
- 20 8. A chimera according to claim 7, wherein the variant a hinge-CH<sub>2</sub>-CH<sub>3</sub> variant.
- 25 9. Chimeric leptin selected from the list consisting of:  
leptin 1-167/IgG4 hinge-CH<sub>2</sub>-CH<sub>3</sub>;  
leptin 1-167/IgG4 hinge-CH<sub>2</sub>-CH<sub>3</sub> PE variant;  
leptin 1-167/IgG1 hinge-CH<sub>2</sub>-CH<sub>3</sub>; and  
leptin 1-167/IgG1 hinge-CH<sub>2</sub>-CH<sub>3</sub> GT linker variant.
- 30 10. A process for preparing a chimera according to any one of claims 1 to 8, which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product.
- 35 11. A process according to claim 10, which process comprises the steps of:
  - i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said chimera;
  - ii) transforming a host cell with said vector;

- iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said chimera; and
- iv) recovering said chimera.

5    12. A DNA polymer comprising a nucleotide sequence that encodes a chimera according to any one of claims 1 to 8.

13. A vector which comprises a DNA polymer according to claim 12.

10    14. A host cell transformed or transfected with a DNA polymer according to claim 12 or a vector according to claim 13.

15    15. A pharmaceutical composition comprising a chimera as claimed in claim 1 and a pharmaceutically acceptable carrier.

16. A chimera according to claim 1, for use as an active therapeutic substance.

17. A chimera according to claim 1, for use in the treatment of obesity or diseases associated with obesity.

20    18. A method for the treatment of obesity or diseases associated with in human or non-human mammal, which method comprises administering to the sufferer an effective, non-toxic amount of a chimera as claimed in claim 1.

25    19. A chimera as claimed in claim 1, for use in the cosmetic treatment of human or non-human mammals.

20. A method for the cosmetic treatment of a human or non-human mammal, which treatment comprises administering an effective, non-toxic amount of a compound of the invention to a human or non-human mammal in need thereof.